Jardiance Cost in Kansas 2026: Prices, Coverage, and Cheaper Alternatives

What Does Jardiance Actually Cost in Kansas Right Now?

The Boehringer Ingelheim and Eli Lilly manufacturer list price for Jardiance sits at approximately $680 per month in 2026, a figure that applies consistently across Kansas retail pharmacies whether you fill at a Walgreens in Wichita or an independent pharmacy in Salina. Without insurance or a savings program, that cash price is the number you will see at the counter.

That $680 figure reflects the wholesale acquisition cost for a 30-tablet supply of either the 10 mg or 25 mg tablet strength. Pharmacy dispensing fees and local markup can push the final out-of-pocket number slightly higher, typically by $10 to $30 depending on the pharmacy. GoodRx and similar coupon aggregators occasionally show prices closer to $550 to $600 at select Kansas locations, but availability of those coupons varies by pharmacy and by month.

Empagliflozin belongs to the SGLT2 inhibitor drug class. The FDA approved it first for type 2 diabetes glycemic control, then expanded approvals followed for cardiovascular risk reduction in adults with established cardiovascular disease, heart failure with reduced ejection fraction, and chronic kidney disease progression [1]. Each of those indications rests on large outcomes data, most notably the EMPA-REG OUTCOME trial published in the New England Journal of Medicine in 2015 [2].

Patients paying full cash price for a chronic medication in the $600 to $700 range face a genuine adherence problem. A 2023 analysis in JAMA Internal Medicine found that high cost-sharing for SGLT2 inhibitors was independently associated with lower 180-day medication adherence among Medicare Part D beneficiaries [3]. Kansas patients who stop empagliflozin because of cost forfeit clinically meaningful cardiovascular and renal protection.

Does Kansas Medicaid Cover Jardiance?

Kansas Medicaid covers Jardiance for the type 2 diabetes indication only. Coverage for the heart failure and chronic kidney disease indications is not currently included on the KanCare preferred drug list as of 2026.

KanCare, the managed-care organization model through which Kansas administers its Medicaid program, operates three managed care organizations: Aetna Better Health of Kansas, Sunflower Health Plan, and United Healthcare Community Plan. Each MCO publishes its own formulary, and all three follow the state-determined preferred drug list for SGLT2 inhibitors. As of the 2026 benefit year, empagliflozin appears on the KanCare PDL with prior authorization required for the type 2 diabetes indication [4].

Prior authorization for KanCare typically requires documentation of an HbA1c above 7.0%, a confirmed diagnosis of type 2 diabetes, and evidence that at least one first-line agent (usually metformin) was trialed or contraindicated. Approval is generally valid for 12 months before re-authorization is needed.

Patients enrolled in Medicare Part D face a separate set of rules. The Inflation Reduction Act of 2022 capped out-of-pocket drug costs for Medicare beneficiaries at $2,000 per year beginning in 2025, which reduces the annual exposure for high-cost drugs like Jardiance significantly [5]. Kansas Medicare beneficiaries should confirm their specific Part D plan formulary tier placement, since Jardiance is classified as a Tier 3 or Tier 4 specialty drug on most plans.

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend SGLT2 inhibitors as a preferred add-on to metformin for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, noting that "the cardiovascular and renal benefits of SGLT2 inhibitors appear to be largely independent of glucose-lowering" [6]. That clinical guidance underscores why the current Kansas Medicaid coverage gap for the HF and CKD indications is a practical problem for affected patients.

How Does the Boehringer Ingelheim / Lilly Savings Card Work for Kansas Patients?

Commercially insured Kansas patients who meet eligibility criteria may pay as little as $10 per month for Jardiance through the Boehringer Ingelheim and Eli Lilly co-pay savings card program.

The savings card is available directly at Jardiance.com and through the manufacturer's patient services line. Eligible patients must have commercial insurance (private employer-sponsored or individual market plans) that covers Jardiance. Government-funded insurance including Medicare, Medicaid, TRICARE, and VA benefits disqualifies a patient from using the co-pay card, which is a federal anti-kickback compliance rule that applies nationwide, not just in Kansas.

For Kansas patients who qualify, the mechanics are straightforward. The card functions like a secondary insurance at the pharmacy. The patient's primary insurance pays its contracted share, and the savings card covers the remaining patient responsibility up to the program maximum, which Boehringer Ingelheim has set at $150 per fill in recent program years. For most commercially insured patients whose plan places Jardiance on Tier 3 with a $40 to $80 co-pay, the card effectively zeroes out the monthly cost.

Patients without insurance who do not qualify for Medicaid and who are not yet on Medicare represent the hardest coverage gap. These patients face the full $680 list price unless they access manufacturer patient assistance, a coupon program, or compounded empagliflozin.

The Boehringer Ingelheim Cares Foundation operates a patient assistance program (PAP) that provides Jardiance at no cost to uninsured or underinsured patients with income at or below 400% of the federal poverty level. Kansas patients can apply through the NeedyMeds database or directly through the manufacturer's access program [7]. Processing typically takes two to four weeks, and a 90-day supply is usually provided per approval cycle.

Is Compounded Empagliflozin Legal in Kansas?

Compounded empagliflozin is legal in Kansas when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. It is not the same product as brand-name Jardiance and carries different regulatory status.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare patient-specific formulations of drugs that are not on the FDA's Demonstrably Difficult to Compound list [8]. Empagliflozin is not currently on that list, which means 503A pharmacies in Kansas and those licensed to ship into Kansas may legally compound it when a licensed prescriber writes a patient-specific prescription.

The cost difference is substantial. Compounded empagliflozin from a 503A pharmacy typically runs $60 to $120 per month depending on dose and formulation, compared with the $680 brand-name list price. Some telehealth platforms that specialize in cardiometabolic conditions offer compounded empagliflozin at the lower end of that range as part of a care package that includes prescriber visits.

503B outsourcing facilities, which produce larger batches without individual prescriptions, are held to Current Good Manufacturing Practice standards. Compounded products from either 503A or 503B facilities are not FDA-approved, meaning the FDA has not evaluated them for safety, efficacy, or consistency of manufacturing the way it has evaluated Jardiance itself [8]. That is a meaningful distinction for patients and prescribers to understand.

The Kansas State Board of Pharmacy regulates in-state compounding pharmacies. Out-of-state pharmacies shipping compounded empagliflozin into Kansas must hold a Kansas non-resident pharmacy license. Patients should verify licensure before ordering. The FDA's BeSafeRx campaign provides guidance on verifying online pharmacy legitimacy [9].

From a clinical standpoint, SGLT2 inhibitors as a class carry a class-wide warning for diabetic ketoacidosis, urinary tract infections, genital mycotic infections, and volume depletion [1]. These risks apply regardless of whether the empagliflozin is brand-name or compounded. Prescribers writing for compounded empagliflozin should apply the same clinical screening criteria they would use for Jardiance.

What Clinical Evidence Supports Empagliflozin at This Price?

Empagliflozin's outcomes data is among the strongest in cardiovascular and renal medicine, which is why specialists argue the drug's cost must be weighed against the events it prevents.

EMPA-REG OUTCOME (N=7,020) randomized patients with type 2 diabetes and established cardiovascular disease to empagliflozin 10 mg or 25 mg versus placebo on top of standard care. At a median follow-up of 3.1 years, empagliflozin reduced the primary composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [2]. Cardiovascular death alone fell by 38% (HR 0.62 to 95% CI 0.49 to 0.77).

The EMPEROR-Reduced trial (N=3,730) tested empagliflozin 10 mg in patients with heart failure with reduced ejection fraction, irrespective of diabetes status. The primary endpoint, a composite of cardiovascular death or hospitalization for heart failure, fell by 25% (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) [10].

The EMPA-KIDNEY trial (N=6,609) enrolled patients with CKD at high risk of progression. Empagliflozin 10 mg reduced the composite of kidney disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [11]. The trial was stopped early by the independent data monitoring committee because the benefit was so clear.

Taken together, these trials represent over 17,000 patients across cardiovascular and renal risk strata. For a Kansas patient with established heart failure paying $680 per month out of pocket, the drug's cost-effectiveness ratio compares favorably with other accepted cardiovascular interventions when downstream hospitalization costs are modeled. A 2022 analysis in Circulation: Cardiovascular Quality and Outcomes estimated the incremental cost-effectiveness ratio for empagliflozin in HFrEF at approximately $47,000 per quality-adjusted life year, below the conventional $100,000 per QALY threshold used in U.S. payer decisions [12].

Which Private Insurance Plans Cover Jardiance in Kansas?

Most major commercial insurance plans sold in Kansas cover Jardiance, though tier placement and prior authorization requirements vary significantly by plan.

Blue Cross and Blue Shield of Kansas places empagliflozin on its standard formulary with prior authorization for the type 2 diabetes indication at Tier 3. Tier 3 co-pays for BCBS of Kansas commercial plans typically run $40 to $70 per 30-day fill depending on the plan design. Aetna, Cigna, and United Healthcare plans sold through the Kansas exchange or employer groups similarly list empagliflozin on Tier 3 or Tier 4, with prior authorization standard across all plans for brand-name SGLT2 inhibitors.

Prior authorization criteria for commercial plans in Kansas generally mirror each other. Prescribers typically need to document the patient's diagnosis code (E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD), confirm that the indication matches the requested formulary tier, and in some cases provide recent lab values including HbA1c, eGFR, or BNP/NT-proBNP depending on the indication sought.

Kansas Insurance Department regulations require that health plans operating in the state comply with state network adequacy and coverage standards, though those standards do not mandate specific drug coverage beyond essential health benefits. Patients who believe a denial was improper may file an appeal with the insurer and, if the internal appeal fails, request an independent external review through the Kansas Insurance Department [13].

The American Heart Association and American College of Cardiology 2022 Guideline for the Management of Heart Failure gives empagliflozin a Class I, Level of Evidence A recommendation for patients with HFrEF, stating that "SGLT2 inhibitors are recommended in patients with symptomatic chronic HFrEF to reduce hospitalization for HF and cardiovascular mortality" [14]. Insurers who deny coverage for the heart failure indication on grounds of experimental or investigational status are acting contrary to guideline consensus.

Can Kansas Patients Get a Jardiance Prescription via Telehealth?

Telehealth prescribing of Jardiance is legal in Kansas. A Kansas-licensed prescriber may write a prescription for empagliflozin following a synchronous audio-video telemedicine visit that meets the standard of care.

Kansas law requires that a valid prescriber-patient relationship be established before controlled substances are prescribed remotely, but empagliflozin is not a controlled substance. The Kansas Board of Healing Arts permits prescribing of non-controlled medications via telehealth when the prescriber can adequately evaluate the patient, obtain a relevant history, and document a clinical decision. A baseline metabolic panel including eGFR and urinalysis is standard clinical practice before initiating empagliflozin, and telehealth platforms typically require patients to upload recent lab results or order labs through the platform before the visit.

Telehealth platforms operating in Kansas that focus on cardiometabolic or diabetes care include national services licensed in the state. Prescription turnaround after a completed telehealth visit is generally 24 to 48 hours, with the prescription sent to the patient's preferred pharmacy. For patients accessing compounded empagliflozin through a telehealth service, the prescription may route directly to the platform's partner 503A pharmacy.

Patients should confirm that the telehealth platform employs prescribers with active Kansas licenses. The Kansas Board of Healing Arts maintains a public license verification database where patients can check a prescriber's license status before the visit.

What Is the Cheapest Way to Get Empagliflozin in Kansas?

The least expensive legally available route depends on insurance status. The decision tree is short and concrete.

Commercially insured Kansas patients should apply for the Boehringer Ingelheim / Lilly savings card first. With commercial insurance and the card, most patients pay $10 per month. That is the floor for brand-name Jardiance.

KanCare (Medicaid) enrollees with a type 2 diabetes diagnosis should pursue prior authorization through their managed care organization. Approved patients generally pay a nominal co-pay of $1 to $4 per fill under KanCare benefit rules.

Uninsured Kansas patients with income at or below 400% of the federal poverty level should apply to the Boehringer Ingelheim Cares Foundation PAP before paying cash. Income documentation and a prescriber attestation are required. Processing takes two to four weeks.

Uninsured patients who do not qualify for the PAP, or who need medication before PAP approval arrives, may consider compounded empagliflozin from a licensed 503A pharmacy. At $60 to $120 per month, compounded empagliflozin is not a free option but represents roughly an 80 to 90% cost reduction versus the brand list price. The clinical evidence base was built on FDA-approved Jardiance, not on compounded formulations, and prescribers should document their rationale for the prescribing decision.

GoodRx and similar discount programs can reduce the cash price at select pharmacies to approximately $550 to $620 but rarely approach the savings available through the manufacturer PAP or compounded alternatives for fully uninsured patients.

Medicare Part D beneficiaries in Kansas should compare plans during open enrollment each fall. Formulary tier placement for Jardiance varies across Part D plans sold in Kansas, and the $2,000 annual out-of-pocket cap that took effect in 2025 under the Inflation Reduction Act means that even Tier 4 drugs are more affordable than in prior years for high-utilization patients [5].

A 2021 JAMA study found that among U.S. adults with type 2 diabetes and cardiovascular disease who had a guideline indication for an SGLT2 inhibitor, only 10.4% were actually taking one, with cost cited as the leading modifiable barrier [15]. Closing that gap matters clinically.